Ocumension TherapeuticsOCUTF 52 Debt-to-Equity is 0.05 as of Dec. 2025, which is 400% above its 10-year median of 0.01. GuruFocus rates OCUTF with a GF Score™ of 52/100 and a GF Value™ of $2.82 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 969 Biotechnology companies, Ocumension Therapeutics ranks better than 71.72% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Ocumension Therapeutics's Debt-to-Equity or its related term are showing as below:
OCUTF'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.01 Max: 0.05
Current: 0.05
During the past 8 years, the highest Debt-to-Equity Ratio of Ocumension Therapeutics was 0.05. The lowest was 0.00. And the median was 0.01.
OCUTF's Debt-to-Equity is ranked better than 71.72% of 969
companies
in the Biotechnology industry
Industry Median: 0.16
vs OCUTF: 0.05
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Ocumension Therapeutics Debt-to-Equity Related Terms
Ocumension Therapeutics Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OCUTF vs VRTX, REGN, ALNY: Debt-to-Equity Comparison
For the Biotechnology subindustry, Ocumension Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ocumension Therapeutics Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ocumension Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Ocumension Therapeutics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ocumension Therapeutics (OCUTF) has a Debt-to-Equity of 0.05 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Ocumension Therapeutics and its competitors. This is 400% above median its historical median of 0.01. According to the industry distribution chart, Ocumension Therapeutics ranks #274 out of 969 companies in the Biotechnology industry, placing it in the top 28.3%.
Is Ocumension Therapeutics' Debt-to-Equity too high?
Ocumension Therapeutics' current Debt-to-Equity of 0.05 is 400% above median its 10-year median of 0.01. The Biotechnology industry median Debt-to-Equity is 0.16. Ocumension Therapeutics' value of 0.05 is 68.8% below this industry median. Based on the distribution chart, Ocumension Therapeutics ranks #274 out of 969 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Ocumension Therapeutics has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ocumension Therapeutics' Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ocumension Therapeutics ranks #274 out of 969 companies for Debt-to-Equity. This puts Ocumension Therapeutics in the upper half of its industry. The industry median Debt-to-Equity is 0.16. Ocumension Therapeutics' value of 0.05 is 68.8% below this benchmark. While the company's 10-year median is 0.01 vs. the industry median of 0.16, Ocumension Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 969 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ocumension Therapeutics's current Debt-to-Equity of 0.05 is 68.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Ocumension Therapeutics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ocumension Therapeutics's current Debt-to-Equity is 0.05, which is 400% above median its own 10-year median of 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ocumension Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Ocumension Therapeutics (OCUTF) is currently considered Possible Value Trap. The stock's GF Value™ is $2.82, compared to a current price of $0.70 — trading 75.2% below its estimated fair value. The current Debt-to-Equity is 0.05, which is 400% above median its 10-year median of 0.01 and 68.8% below the Biotechnology industry median of 0.16. Ocumension Therapeutics' overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Ocumension Therapeutics (OCUTF), the current Debt-to-Equity is 0.05 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ocumension Therapeutics (OCUTF) Overvalued in 2026?
Based on GuruFocus' analysis, Ocumension Therapeutics stock appears to be undervalued.
The current stock price of $0.70 is trading 75.2% below its estimated GF Value™ of $2.82.
GuruFocus considers Ocumension Therapeutics to be Possible Value Trap.
Key valuation signals for OCUTF:
Debt-to-Equity: 0.05 (400% above median its 10-year median of 0.01)
GF Value™: $2.82 vs. price of $0.70 (75.2% below fair value)
Industry Position: 68.8% below the Biotechnology median (#274 of 969)
No single metric tells the full story. See the OCUTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.
52GF Score
Get the complete analysis for OCUTF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCUTF has been successfully added to your 
